<http://webisa.webdatacommons.org/396279340>	<http://www.w3.org/ns/prov#value>	"If Sanofi were to breach or terminate the agreement with us, the development and commercialization of KB001-A or other antibodies directed against the" .
<http://webisa.webdatacommons.org/396279340>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/462219669>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/396279340> .
<http://webisa.webdatacommons.org/396279340>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<sec.gov> .